Company Overview and News

 
Hong Kong and China shares drop as Trump Administration gets ‘even tougher on China’

14h scmp
Stocks listed in Hong Kong and China dropped on Monday, on worries the Trump Administration was stepping up its hardline approach to Beijing, which in turn sent markets lower across Asia.
CICHY MPNGY 0700 SNCHY CICHF AACAY CCB AACAF 0939

 
UPDATE 2-China shrugs off weak markets with $3 bln dollar bond sale

2018-10-12 reuters
HONG KONG (Reuters) - China has sold $3 billion of sovereign dollar bonds, its third such sale in the last 14 years and the first one with a 30-year tranche, drawing healthy investor demand against a backdrop of global market turmoil and a trade war with the United States.
CICHY DB CICHF CCB 0939

 
RPT-GRAPHIC-Deepening bear market sees $1 trln wiped off emerging equities since 2018 peak

2018-10-12 reuters
LONDON, Oct 11 (Reuters) - A selloff in global stocks tore like a wrecking ball through emerging equities on Thursday with the key index flirting with its biggest daily tumble since the surprise Brexit vote stunned markets in June 2016.
CICHY BC94 SMSN CICHF CCB SMSD 0939

 
China sells $3 billion in dollar bonds amid market turmoil

2018-10-12 theedgemarkets
HONG KONG (Oct 11): China has sold $3 billion of sovereign dollar bonds, its third such sale in the last 14 years, drawing healthy investor demand against a backdrop of global market turmoil and a trade war with the United States.
CICHY DB CICHF CCB 0939

 
China sells $3 bn in dollar bonds amid market turmoil

2018-10-12 thehindubusinessline
China has sold $3 billion of sovereign dollar bonds, its third such sale in the last 14 years, drawing healthy investor demand against a backdrop of global market turmoil and a trade war with the US.
CICHY DB CICHF CCB 0939

 
China sells $3 billion in dollar bonds amid market turmoil

2018-10-12 financialexpress
China has sold $3 billion of sovereign dollar bonds, its third such sale in the last 14 years, drawing healthy investor demand against a backdrop of global market turmoil and a trade war with the United States. China sold $1.5 billion of five-year bonds at 3.25 percent, $1 billion of 10-year bonds at 3.5 percent and $500 million of 30-year bonds at 4.00 percent, the finance ministry said on Friday.
CICHY DB CICHF CCB 0939

 
UPDATE 1-China sells $3 billion in dollar bonds amid market turmoil

2018-10-12 reuters
HONG KONG (Reuters) - China has sold $3 billion of sovereign dollar bonds, its third such sale in the last 14 years, drawing healthy investor demand against a backdrop of global market turmoil and a trade war with the United States.
CICHY DB CICHF CCB 0939

 
GRAPHIC-Deepening bear market sees $1 trln wiped off emerging equities since 2018 peak

2018-10-11 reuters
LONDON (Reuters) - A selloff in global stocks tore like a wrecking ball through emerging equities on Thursday with the key index flirting with its biggest daily tumble since the surprise Brexit vote stunned markets in June 2016.
CICHY BC94 SMSN CICHF CCB SMSD 0939

 
China eyes major expansion of its ‘too-big-to-fail’ rules

2018-10-10 scmp
Sources say Chinese regulators led by the country’s central bank are set to initially shortlist at least 50 of the country’s largest lenders, insurers and brokerages as possible ‘systemically important financial institutions’
STAN 55BC CBQS CICHY 580001 STAB STAN STAC 2888 SCBFF CICHF CCB 0939

 
What To Do About Emerging Markets

2018-10-08 seekingalpha
Emerging markets have been one of the worst performing asset classes year-to-date, down nearly 12%, and over 20% since their January peak. The drivers of this poor performance include the strengthening U.S. dollar/weakening local currencies, growth concerns, and geopolitical risks. The recent turbulence in Turkey and Argentina has exacerbated the concerns in emerging markets, although both countries are relatively small components of the index.
WAEMX CICHY SCHE CICHF CCB EV CEO EEM 0939

 
Xi Vs. Mao: The Emerging Market Battle

2018-10-08 seekingalpha
In the span of most of our lives, so many economic systems have turned on a dime. Look at Poland, under the Soviet thumb as recently as three decades ago, graduating this month to "developed" status in FTSE Russell Indexes. China, even after opening up upon Deng Xiaoping's ascension to power in 1978, remained thoroughly communist for years, really engaging freer market reforms only after its Tiananmen Square fiasco in 1989.
CICHY CXSE WCHN CICHF CCB 0939

 
Hong Kong stocks, currency slide on growing pessimism over economy

2018-10-04 scmp
Hong Kong stocks declined across the board on Thursday because a rally in the US dollar overnight caused the city’s currency as well as offshore yuan to weaken, triggering pessimism over the economic outlook.
CICHY 55BC 0700 SOTGY CBQS 2382 CICHF SNPTF CCB 0939

 
Hong Kong stocks slip as China’s manufacturing slows, fuelling fears of expanding impact from trade war

2018-10-02 scmp
Hong Kong stock market reopened lower on Tuesday, hit by declines in Chinese gas distributors Enn Energy Holdings and China Resources Gas Group after a local Chinese government announced plans to launch pricing reforms for the sector, and China’s weaker-than-expected manufacturing data that fuelled worries of overall economic growth.
STAN DB XNGSF CGASY AAIGF 0384 CICHY CGHLY 580001 STAB XNGSY STAN STAC 2888 SCBFF AAGIY CICHF CCB CGHOF 0939

 
Asia Markets: Nikkei gives up early gains as Asian markets sag

2018-10-02 marketwatch
Asian stock markets were down in early trading Tuesday, as Japanese stocks gave up early gains and Hong Kong stocks sank as tensions between the U.S. and China rose.
CICHY CICHF CCB 0939

 
China market rises most in two years as pension funds get OK to invest in stocks

2018-09-26 scmp
China’s stock market rose the most in two years on Tuesday after the first batch of 14 pension target funds were approved by the China Securities Regulatory Commission, a move that is expected to draw inflows into mainland equities. The Hong Kong market rose in line, with gains led by China Evergrande Group.
CRBJY SBMFF GELYF SBHMY GELYY 0386 1177 0175 CICHY 1109 CRBJF 2007 0700 SNCHY CICHF CCB 0939

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...